WIPO logo
Mobile | Deutsch | English | Español | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Recherche dans les collections de brevets nationales et internationales
World Intellectual Property Organization
Options de navigation
Quoi de neuf
Traduction automatique
Dernières données bibliographiques dont dispose le Bureau international   

N° de publication :    WO/2003/082859    N° de la demande internationale :    PCT/EP2003/003470
Date de publication : 09.10.2003 Date de dépôt international : 02.04.2003
Demande présentée en vertu du Chapitre 2 :    09.10.2003    
C07D 401/14 (2006.01), C07D 403/04 (2006.01), C07D 403/14 (2006.01)
Déposants : NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH) (AE, AG, AL, AM, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MC, MD, MK, MN, MX, NI, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, UZ, VC, VN, YU, ZA, ZW only).
NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT) (AT only).
EVENOU, Jean-Pierre [FR/FR]; (FR) (US Seulement).
VON MATT, Peter [CH/CH]; (CH) (US Seulement).
WAGNER, Jürgen [DE/CH]; (CH) (US Seulement).
ZENKE, Gerhard [DE/DE]; (DE) (US Seulement)
Inventeurs : EVENOU, Jean-Pierre; (FR).
VON MATT, Peter; (CH).
WAGNER, Jürgen; (CH).
ZENKE, Gerhard; (DE)
Mandataire : GROSS, Florent; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH)
Données relatives à la priorité :
0207729.5 03.04.2002 GB
0303323.0 13.02.2003 GB
Abrégé : front page image
(EN)Provided are compounds of Formula (I), which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infraction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of (I) are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto’s thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, e.g. angiopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren’s syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn’s disease or ulcerative colitis.
(FR)L'invention concerne des composés représentés par la formule (I), qui possèdent d'intéressantes propriétés pharmacologiques.
États désignés : AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
Office eurasien des brevets (OEAB) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
Office européen des brevets (OEB) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
Langue de publication : anglais (EN)
Langue de dépôt : anglais (EN)